All articles by MarketLine  

  1. Can BMS make a success of its Celgene acquisition?

    Pharmaceutical company Bristol-Myers Squibb (BMS) has bought US biotech Celgene for $74bn as it seeks to leave its troubles behind….
    Read More…

    10 Jan

Go Top